Insider Purchases: Inside the Buy

Tag: Growth at a reasonable price

Illustration of a digital tollbooth standing on the Information Superhighway. Businesses, schools, and government agencies drive cloud servers, laptops, and AI robots through the toll plaza while CDW operators collect technology tolls.

🖥️ CDW Corporation (CDW): The Tech Infrastructure Tollbooth Trading at an Uncharacteristic Discount

CDW Corporation may not build AI chips, but it helps organizations deploy the technology revolution. With insider buying, strong earnings, a growing buyback program, and a forward P/E of just 11.2x, this tech infrastructure giant could be trading at one of its most attractive valuations in years.

Read entire article

Tags: buy or sell CDW, cdw, cdw stock, CDWCorp, ChrisLeahy, cloud computing, cloud infrastructure, cybersecurity, dividend stocks, enterprise software, EnterpriseIT, featured-insiders, funanc1al, GARP, garp investing, growth at a reasonable price, hub-insiders, insider buying, InsiderBuying, institutional ownership, nasdaq cdw, risks buying CDW, stock analysis, tech investing, technology stocks, TechStocks, value stocks, ValueInvesting, why buy CDW
Illustration of futuristic Celsius energy drink cans glowing with electric neon colors inside a high-performance trading floor and fitness environment hybrid, surrounded by rising stock charts, athletes, institutional investors, and explosive energy waves

⚡ Celsius Holdings (CELH): Wall Street Panicked. Insiders Bought the Dip

Celsius Holdings (CELH) may no longer be just a trendy fitness energy drink brand. With explosive 138% revenue growth, synchronized insider buying, Alani Nu integration success, and PepsiCo’s distribution engine accelerating expansion, the stock increasingly looks like a high-growth GARP opportunity hiding beneath a brutal valuation reset.

Read entire article

Tags: Alani Nu, AlaniNu, beverage industry, beverage stocks, BeverageIndustry, buy or sell CELH, CELH, CELH stock, Celsius Holdings, CelsiusHoldings, CEO John Fieldly, consumer brands, consumer discretionary, Director Hal Kravitz, energy drink stocks, featured-insiders, fitness stocks, FUNanc1al, FUNanc1al investing, functional beverages, FunStock, GARP, GARP investing, growth at a reasonable price, growth stocks, GrowthStocks, health and wellness stocks, hub-insiders, insider buying, InsiderBuying, momentum stocks, NASDAQ stocks, PepsiCo partnership, President & COO Eric Hanson, risks buying CELH, Rockstar Energy, short squeeze stocks, stock market analysis, ValueInvesting, Wall Street analysts, why buy CELH
A confident businesswoman holds a glowing blue DNA helix like a lightsaber, standing against a golden background with a rising stock chart and the Vertex Pharmaceuticals logo—symbolizing innovation, biotech strength, and market growth.

CEO Bought Shares of Vertex Pharmaceuticals (VRTX) A Bit Higher Back in August: Great Biotech At A Fair Price. Wait For Additional Pull-Back?

Vertex is more than cystic fibrosis drugs. With gene editing, pain relief, and even a potential T1D cure, the CEO’s insider buy raises one question: buy now or wait for additional pullback?

 

Read entire article

Tags: Biotech Innovation, Biotech Investing, Buy VRTX Stock, CEO Buys, CEO Conviction, CEO insider buying, CEO Stock Purchase, CEOBuyIn, CEOConfidence, Funanc1al, Funanc1al Edge, Funanc1al Investing, Gene editing, Growth at a reasonable price, Reshma Kewalramani, Type 1 diabetes cure, Vertex Pharmaceuticals, VRTX